Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

计划入组 116 人 · 首次发布于 2014 年 1 月 17 日

Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases

计划入组 810 人 · 首次发布于 2026 年 3 月 20 日

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

计划入组 138 人 · 首次发布于 2013 年 2 月 5 日

AHN-649

NS-649

AIC-649

EverEx, Inc.

South Korea

Tetris Pharma Ltd.

United Kingdom

Mereo BioPharma

United Kingdom

Nivolumab Plus Chemotherapy Demonstrates Sustained Survival Benefit in Advanced Gastroesophageal Cancers

FDA Advisory Committee Recommends Against Checkpoint Inhibitors for Certain Gastroesophageal Cancers

FLOT Regimen Emerges as Superior Treatment for Localized Gastroesophageal Cancer, Outperforming Radiation Therapy